{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of CI was not estimable due to the relatively short duration of follow-up.","groupId":"OG000","lowerLimit":"1.84","upperLimit":"NA","value":"4.86"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"5.39","value":"3.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Time to progression was defined as the number of days from the date of first dose of daratumumab to the date of first record of disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All treated analysis set included all participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"Up to 14.4 Months","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"months"}